Global Search | Novartis

Showing 2679 results

Media Release / Mar 19, 2025

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA

Treatment with investigational OAV101 IT led to statistically significant 2.39-point improvement on the HFMSE vs. 0.51 points in sham control armSafety findings were consistent in both treatment-…
Key Release / Mar 28, 2025

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI)…
Clinical Trials / Mar 27, 2025

Asciminib Roll-over Study
Clinical Trials / Mar 27, 2025

Iptacopan in Patients With ANCA Associated Vasculitis
Clinical Trials / Mar 25, 2025

Modifying PEST for Psoriatic Arthritis Screening
Clinical Trials / Mar 25, 2025

LATAM LOWERS LDL-C
Clinical Trials / Mar 27, 2025

Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Clinical Trials / Mar 25, 2025

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Clinical Trials / Mar 25, 2025

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Clinical Trials / Mar 25, 2025

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia